New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
12:17 EDTSGMOSangamo presents clinical data at CROI from SB-728-T program
Sangamo BioSciences announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections. The conference is being held in Boston from March 3 to 6. Data from an earlier Phase 1 clinical study in this program were also published in the March 6, 2014 issue of the New England Journal of Medicine. At CROI, data were reported from a Phase 1 /2 clinical trial, SB-728-1101, designed to evaluate the effect of increasing doses of Cytoxan preconditioning as a method to increase the numbers of circulating T-cells, including cells that were zinc finger nuclease modified at the CCR5 gene. The data demonstrate that increasing doses of Cytoxan preconditioning prior to a single infusion of SB-728-T led to a dose-dependent increase in both engraftment of CCR5-modified cells and notable increases in total CD4 cells above the baseline. In addition, researchers observed the greatest decrease in viral load during a treatment interruption from antiretroviral therapy at the highest Cytoxan dose (1.0 g/m2). Two of the three subjects treated at this dose remain on TI with detectable but stable VLs of several weeks duration. In addition, Sangamo updated the status of a subject from its SB-728-902, Cohort 5 study, who has demonstrated ongoing control of VL for 31 weeks without ART, and who remains on TI.
News For SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
16:12 EDTSGMOSangamo backs FY14 revenue view $45M-$50M, consensus $47.57M
Subscribe for More Information
16:06 EDTSGMOSangamo reports Q3 EPS (11c), consensus (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use